GLGuangming Li

Guangming Li

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Guangming Li has a total of 57 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    In vitro NAD + supplementation increases CD4 + and CD8 + T cell function in people with HIV

    by Guangming Li, Salma Sharaf, Yaoxian Lou, Lishan Su, Shyam Kottilil, Poonam Mathur

    Objectives: HIV perturbs T cell homeostasis and disrupts immune function, increasing the risk of age‐associated comorbidities. Ageing people with HIV (PWH) have exacerbated expression of CD38 on T cells, which depletes intracellular nicotinamide adenine dinucleotide (NAD+). We investigated whether boosting intracellular NAD+ could restore T cell homeostasis and function. Methods: We collected blood samples from virally suppressed PWH to determine the effects of in vitro NAD+ on CD38 expression and T cell function in response to anti‐CD3/CD28 antibodies stimulation in PBMCs culture supplemented with IL‐2 and IL‐7. Results: We observed that NAD+ supplementation not only reduced expression of CD38 but also improved T cell function with an alleviated exhaustion phenotype in response to anti‐CD3/CD28 antibodies stimulation. Conclusions: If confirmed in clinical trials, NAD+ supplementation has the potential to restore T cell homeostasis and immune function in PWH and ameliorate age‐associated comorbidities.

  • High-avidity cathepsin-G–specific CAR T cells for the treatment of acute myeloid leukemia

    by Tara Walhart, Marta Biondi, Simone Stucchi, Guangming Li, Ourania Tsahouridis, Peishun Shou, Kyogo Suzuki, Elizabeth G. Hunt, Andrew Kennedy, Jessica E. Thaxton, et al.

    Chimeric antigen receptor (CAR) T cells specific for myeloid-associated antigens expressed on the cell surface of acute myeloid leukemia (AML) can cause depletion of normal myeloid progenitor cells. We developed a CAR specific for an HLA-A∗02:01-restricted peptide of the myeloid-restricted cathepsin-G (CG) protein. CG-specific CAR T cells (CG1.CAR) were further engineered to increase their functional avidity. Specifically, we developed CG1.CAR T cells coexpressing the lymphocyte-specific protein tyrosine kinase (LCK) and duplicated CD3ζ chain, which allows the functional recognition of the CG1 peptide as low as 0.025μM. Optimized CG1.CAR T cells displayed antileukemia effects in vitro and in vivo in patient-derived AML xenotransplant mouse models and did not cause hematopoietic toxicity in colony assays and humanized mice. Mechanistically, LCK overexpression in CG1.CAR T cells caused transcriptional modifications characterized by the overexpression of mitochondrial-encoded electron transport chain components that were correlated with increased mitochondrial mass and improved respiratory capacity. Based on these data, CG1.CAR T cells hold clinical potential for the treatment of AML.

  • Open Access

    Antibody glyco-optimization and site-specific conjugation enhance the immune-stimulating activity of antibody-TLR ligand conjugates

    by Xianyang Wang, Yaoxian Lou, Helena Yun, Margaryta Gomozkova, Guangming Li, Lishan Su, Lai-Xi Wang

  • Depletion of plasmacytoid dendritic cells rescues HIV-reactive stem-like CD8 + T cells during chronic HIV-1 infection

    by Guangming Li, Yaoxian Lou, Jianping Ma, Liang Cheng, Haisheng Yu, Ourania Tsahouridis, Xiuting He, Masaya Funaki, James Ahodantin, Wenwen Bi, et al.

    Plasmacytoid dendritic cells (pDCs) rapidly produce type I interferon (IFN-I) in response to acute virus infections. During chronic HIV-1 infection, persistent activation of pDCs contributes to inflammatory diseases. Combination antiretroviral therapy (cART) effectively suppresses HIV-1 replication and prolongs the life span of people living with HIV-1 (PLWH). The persistence of viral reservoir cells under cART, however, is associated with suboptimal immune reconstitution, impaired anti-HIV immunity, and non–AIDS-defining inflammatory diseases through unclear mechanisms. We report here that pDC depletion in HIV-infected humanized mice with suppressive cART alleviated HIV-associated inflammation, reversed T cell immune exhaustion, enhanced HIV-specific CD8 + T cell responses, and reduced HIV-1 reservoirs in lymphoid and nonlymphoid tissues through CD8 + T cell–dependent mechanisms. Specifically, pDC depletion in the mice led to an increase in TCF-1 + PD-1 + Tim-3 − stem-like memory CD8 + T cells in HIV-infected lymphoid tissues, which correlated with a reduction in the HIV-1 reservoir. We further showed that pDCs suppressed the polyfunctional activity of anti-HIV stem-like memory CD8 + T cells isolated from PLWH in vitro. As in the HIV-infected humanized mice, pDC depletion or IFN-I blockade functionally rescued the stem-like memory CD8 + T cells, enhancing their anti-HIV responses. Combination therapy with PD-1 blockade further improved stem-like memory T cell function both in vitro and in HIV-infected humanized mice. Our findings indicate that HIV-induced inflammatory pDCs impair anti-HIV stem-like memory CD8 + T cell responses and suggest that the combination of pDC depletion with PD-1 immune checkpoint blockade represents a candidate therapeutic approach to treating HIV-1 infection and its associated inflammatory diseases.


  • Open Access

    CD24-Fc resolves inflammation and enhances anti-HIV CD8 T cells with polyfunctionality during HIV-1 infection under cART

    by Guangming Li, Jianping Ma, Haisheng Yu, Ourania Tsahouridis, Yaoxian Lou, Xiuting He, Masaya Funaki, Pan Zheng, Yang Liu, Lishan Su

    The persistence of HIV-1 reservoirs during combination anti-retroviral therapy (cART) is associated with chronic inflammation and systemic immune activation in people infected with HIV-1 (PWH), leading to a suboptimal immune reconstitution as well as an increased risk of non-AIDS events. In this study, we assessed the effect of CD24-Fc, a fusion protein with anti-inflammatory properties that interacts with danger-associated molecular patterns (DAMPs) and siglec-10, in humanized mice with chronic HIV-1 infection under suppressive cART in vivo and in peripheral blood mononuclear cells (PBMCs) from PWH in vitro. We report that CD24-Fc treatment significantly reduced inflammation and immune hyperactivation in humanized mice with HIV-1 infection and cART. CD24-Fc treatment improved recovery of CD4 T cells, reduced immune hyper-activation, increased functional central memory T cells. Notably, CD24-Fc treatment increased CXCR5 + CD8 central memory T cells (TCM) with increased HIV-specific polyfunctionality in humanized mice and in PBMC from PWH. This enhanced anti-HIV T cell activity was associated with improved control of HIV-1 viral rebound and reduced HIV-1 pathogenesis upon cART cessation. Our findings indicate that CD24-Fc may provide a promising new therapeutic for treating chronic inflammation and associated diseases in PWH.